Interferon-alpha affects the immune response in post-transplant lymphoproliferative disorder

Am J Respir Crit Care Med. 1996 Apr;153(4 Pt 1):1442-7. doi: 10.1164/ajrccm.153.4.8616579.

Abstract

Post-transplant lymphoproliferative disorder (PTLD) is associated with Epstein-Barr virus (EBV) and characterized by fever, lymphadenopathy, and graft dysfunction. We describe the clinical course of an EBV seronegative 11-yr-old boy who underwent double lung transplantation and subsequently developed PTLD in the graft. A reduction in immunosuppression and the addition of acyclovir did not result in improvement. Treatment with interferon-alpha (IFN-alpha), however, led to dramatic clinical, radiographic, and histologic improvement. Semiquantitative measurements of cytokine mRNA in his bronchoalveolar lavage cells prior to therapy with IFN-alpha revealed high levels of IL-4 and IL-10 mRNA, which decreased significantly with treatment. We speculate that the beneficial effect of IFN-alpha in the treatment of PTLD is directly related to the inhibition of type 2 helper (Th2-like) T-cells.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Bronchoalveolar Lavage Fluid
  • Child
  • Cytokines / analysis*
  • Humans
  • Interferon-alpha / pharmacology
  • Interferon-alpha / therapeutic use*
  • Lung Transplantation / adverse effects
  • Lung Transplantation / immunology*
  • Lymphoproliferative Disorders / drug therapy
  • Lymphoproliferative Disorders / etiology
  • Lymphoproliferative Disorders / immunology*
  • Male
  • Postoperative Complications / immunology*
  • T-Lymphocytes, Helper-Inducer / drug effects
  • T-Lymphocytes, Helper-Inducer / physiology
  • Transplantation Immunology / immunology

Substances

  • Cytokines
  • Interferon-alpha